State of the art in anti-cancer mAbs
- Autores
- Chiavenna, Sebastián Matias; Jaworski, Juan Pablo; Vendrell, Alejandrina
- Año de publicación
- 2017
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
Instituto de Virología
Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España
Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina - Fuente
- Journal of biomedical science (2017) : 24:15
- Materia
-
Neoplasmas
Anticuerpos Monoclonales
Inmunoterapia
Neoplasms
Monoclonal Antibodies
Immunotherapy
Cáncer (Enfermedad) - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Instituto Nacional de Tecnología Agropecuaria
- OAI Identificador
- oai:localhost:20.500.12123/548
Ver los metadatos del registro completo
id |
INTADig_c446260b80c6bfec7c6e8b82f1ebc492 |
---|---|
oai_identifier_str |
oai:localhost:20.500.12123/548 |
network_acronym_str |
INTADig |
repository_id_str |
l |
network_name_str |
INTA Digital (INTA) |
spelling |
State of the art in anti-cancer mAbsChiavenna, Sebastián MatiasJaworski, Juan PabloVendrell, AlejandrinaNeoplasmasAnticuerpos MonoclonalesInmunoterapiaNeoplasmsMonoclonal AntibodiesImmunotherapyCáncer (Enfermedad)Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.Instituto de VirologíaFil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; EspañaFil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; ArgentinaFil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina2017-07-03T15:04:59Z2017-07-03T15:04:59Z2017-02-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/548https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y1423-0127https://doi.org/10.1186/s12929-016-0311-yJournal of biomedical science (2017) : 24:15reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-04T09:46:53Zoai:localhost:20.500.12123/548instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-04 09:46:53.609INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse |
dc.title.none.fl_str_mv |
State of the art in anti-cancer mAbs |
title |
State of the art in anti-cancer mAbs |
spellingShingle |
State of the art in anti-cancer mAbs Chiavenna, Sebastián Matias Neoplasmas Anticuerpos Monoclonales Inmunoterapia Neoplasms Monoclonal Antibodies Immunotherapy Cáncer (Enfermedad) |
title_short |
State of the art in anti-cancer mAbs |
title_full |
State of the art in anti-cancer mAbs |
title_fullStr |
State of the art in anti-cancer mAbs |
title_full_unstemmed |
State of the art in anti-cancer mAbs |
title_sort |
State of the art in anti-cancer mAbs |
dc.creator.none.fl_str_mv |
Chiavenna, Sebastián Matias Jaworski, Juan Pablo Vendrell, Alejandrina |
author |
Chiavenna, Sebastián Matias |
author_facet |
Chiavenna, Sebastián Matias Jaworski, Juan Pablo Vendrell, Alejandrina |
author_role |
author |
author2 |
Jaworski, Juan Pablo Vendrell, Alejandrina |
author2_role |
author author |
dc.subject.none.fl_str_mv |
Neoplasmas Anticuerpos Monoclonales Inmunoterapia Neoplasms Monoclonal Antibodies Immunotherapy Cáncer (Enfermedad) |
topic |
Neoplasmas Anticuerpos Monoclonales Inmunoterapia Neoplasms Monoclonal Antibodies Immunotherapy Cáncer (Enfermedad) |
dc.description.none.fl_txt_mv |
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice. Instituto de Virología Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina |
description |
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-07-03T15:04:59Z 2017-07-03T15:04:59Z 2017-02-20 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
status_str |
publishedVersion |
format |
article |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/20.500.12123/548 https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y 1423-0127 https://doi.org/10.1186/s12929-016-0311-y |
url |
http://hdl.handle.net/20.500.12123/548 https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y https://doi.org/10.1186/s12929-016-0311-y |
identifier_str_mv |
1423-0127 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
Journal of biomedical science (2017) : 24:15 reponame:INTA Digital (INTA) instname:Instituto Nacional de Tecnología Agropecuaria |
reponame_str |
INTA Digital (INTA) |
collection |
INTA Digital (INTA) |
instname_str |
Instituto Nacional de Tecnología Agropecuaria |
repository.name.fl_str_mv |
INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria |
repository.mail.fl_str_mv |
tripaldi.nicolas@inta.gob.ar |
_version_ |
1842341347745333248 |
score |
12.623145 |